In total, 1,434 LS DLBCL patients with known MYC-R status, diagnosed between 2014 and 2020, and treated with R-CHOP(-like) regimens, were identified in the NCR including 733 (51%) stage I patients and 701 (49%) stage II patients (Fig. 1). Here, MYC is linked to diffuse large B-cell lymphoma.